Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Baxter
Moodys
AstraZeneca
Harvard Business School

Last Updated: December 7, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VICTOZA

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for VICTOZA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00993720 ↗ Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes Completed Hvidovre University Hospital Phase 2/Phase 3 2009-10-01 The aim of the study is to investigate the effect of Victoza (a GLP-1 receptor agonist)on insulin-dose, risk of hypoglycemia and gastric emptying rate during hypoglycemia in patients with type 1 diabetes.
NCT01029886 ↗ Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes Completed Eli Lilly and Company Phase 3 2010-01-01 No head to head comparisons between exenatide once weekly and liraglutide have been performed. Therefore, the purpose of this study is to compare exenatide once weekly to once-daily liraglutide with regard to HbA1c, body weight, subject-reported outcomes, and other clinical benefits. The study includes a 26-week treatment period and a safety follow-up visit 10 weeks after the final study drug dose.
NCT01029886 ↗ Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes Completed AstraZeneca Phase 3 2010-01-01 No head to head comparisons between exenatide once weekly and liraglutide have been performed. Therefore, the purpose of this study is to compare exenatide once weekly to once-daily liraglutide with regard to HbA1c, body weight, subject-reported outcomes, and other clinical benefits. The study includes a 26-week treatment period and a safety follow-up visit 10 weeks after the final study drug dose.
NCT01226966 ↗ Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes Completed Novo Nordisk A/S 2010-09-01 This observational study is conducted in Europe. The aim of this non-interventional (observational) study is to evaluate the efficacy of liraglutide (Victoza®) and to assess the conditions of use of Victoza® in daily medical practice in France.
NCT01234649 ↗ Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) Completed Novo Nordisk A/S Phase 3 2011-08-11 A diagnosis of gestational diabetes mellitus (GDM)has significant implications for the future health of the mother. GDM is often the culmination of years of unrecognized and unmodified diabetes risk factors that lead to overt and occult clinical manifestations during pregnancy. Systematic reviews of older studies conclude that 35-60% women with gestational diabetes will develop type 2 diabetes (DM2) at rates much greater than control groups who did not have glucose intolerance during pregnancy. Liraglutide may potentially delay disease progression in GDM considering the beta -(ß-)cell function improvement in DM2 and ß-cell mass shown to increase in animal models. This study will examine if the addition of liraglutide to metformin therapy is more effective than metformin alone in improving insulin sensitivity and normalizing insulin secretion in at-risk overweight/obese women with prior GDM.
NCT01234649 ↗ Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) Completed Woman's Phase 3 2011-08-11 A diagnosis of gestational diabetes mellitus (GDM)has significant implications for the future health of the mother. GDM is often the culmination of years of unrecognized and unmodified diabetes risk factors that lead to overt and occult clinical manifestations during pregnancy. Systematic reviews of older studies conclude that 35-60% women with gestational diabetes will develop type 2 diabetes (DM2) at rates much greater than control groups who did not have glucose intolerance during pregnancy. Liraglutide may potentially delay disease progression in GDM considering the beta -(ß-)cell function improvement in DM2 and ß-cell mass shown to increase in animal models. This study will examine if the addition of liraglutide to metformin therapy is more effective than metformin alone in improving insulin sensitivity and normalizing insulin secretion in at-risk overweight/obese women with prior GDM.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for VICTOZA

Condition Name

Condition Name for VICTOZA
Intervention Trials
Type 2 Diabetes 23
Type 2 Diabetes Mellitus 17
Obesity 16
Diabetes Mellitus, Type 2 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for VICTOZA
Intervention Trials
Diabetes Mellitus 62
Diabetes Mellitus, Type 2 56
Diabetes Mellitus, Type 1 13
Fatty Liver 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for VICTOZA

Trials by Country

Trials by Country for VICTOZA
Location Trials
United States 152
China 27
Canada 24
Denmark 20
Germany 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for VICTOZA
Location Trials
California 11
New York 9
Texas 8
Ohio 7
North Carolina 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for VICTOZA

Clinical Trial Phase

Clinical Trial Phase for VICTOZA
Clinical Trial Phase Trials
Phase 4 42
Phase 3 19
Phase 2/Phase 3 5
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for VICTOZA
Clinical Trial Phase Trials
Completed 71
Unknown status 12
Recruiting 11
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for VICTOZA

Sponsor Name

Sponsor Name for VICTOZA
Sponsor Trials
Novo Nordisk A/S 40
University of Copenhagen 5
Steno Diabetes Center 4
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for VICTOZA
Sponsor Trials
Other 156
Industry 56
NIH 6
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Express Scripts
McKesson
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.